Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DNL952

Other · developed by Denali Therapeutics

Phase 1 Most advanced trial

DNLI Developer

1 Registered trials

What is DNL952?

DNL952 is an intravenously administered agent given as a repeating dose, studied in late-onset Pompe disease (glycogen storage disease type II).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Denali Therapeutics Inc. (DNLI)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07354724	Phase 1	Late-onset Pompe Disease	Recruiting	DNLI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Late-onset Pompe Disease

More from Denali Therapeutics

Tividenofusp Alfa FDA approved DNL126 Phase 1/2 DNL201 Phase 1 DNL343 Phase 2/3 DNL593 Phase 1/2 DNL628 Phase 1 DNL747 Phase 1 DNL919 Phase 1 DNL921 Phase 1

Sources

ClinicalTrials.gov NCT07354724

Updated Oct 11, 2026. Something wrong or missing? Report it on the DNLI page.

Follow DNLI, the company behind DNL952

See DNLI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DNLI catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z